drugset / Trial / NCT00019188

Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00019188

Phase 1/2 Completed National Cancer Institute (NCI)
Treatment

Summary

RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.

Timeline

Start
1997-01
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject interleukin-12 Protein / enzyme biologic Subcutaneous

Indications